Onc Now | Episode 24
In this episode of Onc Now, host Jonathan Sackier welcomes Komal Jhaveri, Breast Medical Oncologist and clinical investigator at Memorial Sloan Kettering Cancer Center, New York, USA. Known for her trailblazing work in HER2-positive, HER2-low, and hormone receptor-positive breast cancers, Komal Jhaveri discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field.
Komal Jhaveri is a Breast Medical Oncologist and Clinical Investigator at Memorial Sloan Kettering Cancer Center, New York, USA. Her research focuses on precision oncology, with a particular emphasis on HER2-positive, HER2-low, and hormone receptor-positive breast cancers. She has led and contributed to numerous landmark trials that have shaped current treatment standards and is actively involved in the development of next-generation targeted therapies, including antibody-drug conjugates.
Timestamps
00:00 – Introduction
02:50 – What initially drew Komal into oncology
04:45 – The future of breast cancer care
06:13 – Possibility of personalised treatments for patients
07:40 – Antibody-drug conjugates
09:30 – How we define HER2 status
14:40 – HER2-low disease
17:40 – Targeted therapy combinations
20:54 – Endocrine resistance
23:18 – The realities of implementing new therapies
28:40 – Promising initiatives on the horizon
31:30 – Komal’s key takeaways
